Inovio Pharmaceuticals (INO) PT Set at $13.00 by HC Wainwright

Inovio Pharmaceuticals (NASDAQ:INO) has been assigned a $13.00 target price by research analysts at HC Wainwright in a research note issued on Friday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 190.18% from the company’s current price.

Other analysts also recently issued reports about the stock. Maxim Group set a $12.00 target price on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, January 2nd. Citigroup initiated coverage on shares of Inovio Pharmaceuticals in a report on Friday, October 6th. They issued a “buy” rating and a $10.00 target price on the stock. Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. Royal Bank of Canada initiated coverage on shares of Inovio Pharmaceuticals in a report on Wednesday, October 18th. They issued an “outperform” rating and a $11.00 target price on the stock. Finally, BidaskClub downgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, October 13th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $19.16.

Shares of Inovio Pharmaceuticals (NASDAQ INO) traded up $0.01 during midday trading on Friday, reaching $4.48. 740,900 shares of the company’s stock were exchanged, compared to its average volume of 1,290,000. The company has a market cap of $402.72, a P/E ratio of -3.80 and a beta of 2.74. Inovio Pharmaceuticals has a one year low of $4.09 and a one year high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.15). Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. The business had revenue of $2.60 million during the quarter, compared to the consensus estimate of $10.27 million. During the same quarter last year, the firm earned ($0.28) earnings per share. The business’s quarterly revenue was down 79.2% on a year-over-year basis. analysts forecast that Inovio Pharmaceuticals will post -1.12 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in shares of Inovio Pharmaceuticals by 4.2% during the 2nd quarter. Vanguard Group Inc. now owns 3,227,219 shares of the biopharmaceutical company’s stock worth $25,301,000 after purchasing an additional 129,164 shares during the period. Wasatch Advisors Inc. boosted its stake in shares of Inovio Pharmaceuticals by 3.1% during the 3rd quarter. Wasatch Advisors Inc. now owns 2,691,331 shares of the biopharmaceutical company’s stock worth $17,063,000 after purchasing an additional 80,513 shares during the period. Northern Trust Corp boosted its stake in shares of Inovio Pharmaceuticals by 2.8% during the 2nd quarter. Northern Trust Corp now owns 896,472 shares of the biopharmaceutical company’s stock worth $7,028,000 after purchasing an additional 24,366 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Inovio Pharmaceuticals by 17.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 382,206 shares of the biopharmaceutical company’s stock worth $2,423,000 after purchasing an additional 56,623 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of Inovio Pharmaceuticals by 9.2% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 334,017 shares of the biopharmaceutical company’s stock worth $2,619,000 after purchasing an additional 28,173 shares during the period. 32.12% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/01/15/inovio-pharmaceuticals-ino-pt-set-at-13-00-by-hc-wainwright-2.html.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply